Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Cash from Operations (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Cash from Operations for 6 consecutive years, with 3090000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 2.92% to 3090000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 33279000.0, a 216.78% increase, with the full-year FY2025 number at 33279000.0, up 216.78% from a year prior.
  • Cash from Operations was 3090000.0 for Q4 2025 at GeneDx Holdings, down from 15767000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 15767000.0 in Q3 2025 to a low of 88362000.0 in Q3 2022.
  • A 5-year average of 34247650.0 and a median of 35543000.0 in 2023 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: plummeted 19292.69% in 2021, then skyrocketed 458.75% in 2025.
  • GeneDx Holdings' Cash from Operations stood at 51985000.0 in 2021, then decreased by 24.37% to 64654000.0 in 2022, then surged by 53.82% to 29858000.0 in 2023, then skyrocketed by 89.34% to 3183000.0 in 2024, then rose by 2.92% to 3090000.0 in 2025.
  • Per Business Quant, the three most recent readings for WGS's Cash from Operations are 3090000.0 (Q4 2025), 15767000.0 (Q3 2025), and 10420000.0 (Q2 2025).